Key result
This study protocol outlines a comparative effectiveness analysis of five oral anticoagulants versus no extended treatment for deep venous thrombosis and pulmonary embolism.
Why the study?
How do dabigatran, apixaban, rivaroxaban, edoxaban, warfarin, and no extended treatment compare regarding recurrence reduction and bleeding risk for the extended treatment of DVT and PE?
Observational
How do dabigatran, apixaban, rivaroxaban, edoxaban, warfarin, and no extended treatment compare regarding recurrence reduction and bleeding risk for the extended treatment of DVT and PE?
This study protocol outlines a comparative effectiveness research study to evaluate five oral anticoagulants and no treatment for extended DVT/PE management.
Answers are grounded in this paper and cite their sources.
This protocol does not change VTE anticoagulation practice; leaves open comparative effectiveness of five oral agents versus no extension.
Since 2010, four oral anticoagulants have been approved for marketing in addition to warfarin for treatment of thromboembolic disease. Limited head-to-head data exist comparing these treatments, leaving patients and clinicians with little guidance for selecting a strategy that balances recurrence reduction with bleeding risk. In the dabigatran, apixaban, rivaroxban, edoxaban and warfarin comparative effectiveness research study, we compare all five currently available oral anticoagulant agents for the extended treatment of deep venous thrombosis and pulmonary embolism, as well as no extended treatment, and evaluate whether results differ in specific sub-populations. As our population includes Medicare novel anticoagulant users and large numbers of commercially insured and Medicaid patients, our results will likely be transportable to the majority of US patients experiencing a DVT or pulmonary embolism. CLINICAL TRIALS REGISTRATION: NCT03271450.
No takes yet. Share an insight, caveat, or question.
Krumme et al. (2017) conducted an observational in deep venous thrombosis and pulmonary embolism. dabigatran, apixaban, rivaroxaban, edoxaban, warfarin vs. no extended treatment was evaluated. This study protocol outlines a comparative effectiveness analysis of five oral anticoagulants versus no extended treatment for deep venous thrombosis and pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: